Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation
Type 2 diabetes (T2D) is an independent risk factor of stroke and systemic embolism in patients with atrial fibrillation (AF), and T2D patients with AF-associated stroke seem to have worse clinical outcome and higher risk of unfavorable clinical course compared to individuals without this metabolic...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2019/5158308 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556188081848320 |
|---|---|
| author | Dana Prídavková Matej Samoš Tomáš Bolek Ingrid Škorňová Jana Žolková Peter Kubisz Ján Staško Marián Mokáň |
| author_facet | Dana Prídavková Matej Samoš Tomáš Bolek Ingrid Škorňová Jana Žolková Peter Kubisz Ján Staško Marián Mokáň |
| author_sort | Dana Prídavková |
| collection | DOAJ |
| description | Type 2 diabetes (T2D) is an independent risk factor of stroke and systemic embolism in patients with atrial fibrillation (AF), and T2D patients with AF-associated stroke seem to have worse clinical outcome and higher risk of unfavorable clinical course compared to individuals without this metabolic disorder. Long-term anticoagulation is indicated in majority of T2D patients with AF to prevent adverse AF-associated embolic events. Direct oral anticoagulants (DOACs), direct oral thrombin inhibitor dabigatran, and direct oral factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, have emerged as a preferred choice for long-term prevention of stroke in AF patients offering potent and predictable anticoagulation and a favorable pharmacology with low risk of interactions. This article reviews the current data regarding the use of DOACs in individuals with T2D and AF. |
| format | Article |
| id | doaj-art-65a50962082648c3a0445471b3c7e0aa |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-65a50962082648c3a0445471b3c7e0aa2025-02-03T05:45:58ZengWileyJournal of Diabetes Research2314-67452314-67532019-01-01201910.1155/2019/51583085158308Type 2 Diabetes, Atrial Fibrillation, and Direct Oral AnticoagulationDana Prídavková0Matej Samoš1Tomáš Bolek2Ingrid Škorňová3Jana Žolková4Peter Kubisz5Ján Staško6Marián Mokáň7Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, SlovakiaNational Center of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, SlovakiaNational Center of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, SlovakiaNational Center of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, SlovakiaNational Center of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, SlovakiaType 2 diabetes (T2D) is an independent risk factor of stroke and systemic embolism in patients with atrial fibrillation (AF), and T2D patients with AF-associated stroke seem to have worse clinical outcome and higher risk of unfavorable clinical course compared to individuals without this metabolic disorder. Long-term anticoagulation is indicated in majority of T2D patients with AF to prevent adverse AF-associated embolic events. Direct oral anticoagulants (DOACs), direct oral thrombin inhibitor dabigatran, and direct oral factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, have emerged as a preferred choice for long-term prevention of stroke in AF patients offering potent and predictable anticoagulation and a favorable pharmacology with low risk of interactions. This article reviews the current data regarding the use of DOACs in individuals with T2D and AF.http://dx.doi.org/10.1155/2019/5158308 |
| spellingShingle | Dana Prídavková Matej Samoš Tomáš Bolek Ingrid Škorňová Jana Žolková Peter Kubisz Ján Staško Marián Mokáň Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation Journal of Diabetes Research |
| title | Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation |
| title_full | Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation |
| title_fullStr | Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation |
| title_full_unstemmed | Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation |
| title_short | Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation |
| title_sort | type 2 diabetes atrial fibrillation and direct oral anticoagulation |
| url | http://dx.doi.org/10.1155/2019/5158308 |
| work_keys_str_mv | AT danapridavkova type2diabetesatrialfibrillationanddirectoralanticoagulation AT matejsamos type2diabetesatrialfibrillationanddirectoralanticoagulation AT tomasbolek type2diabetesatrialfibrillationanddirectoralanticoagulation AT ingridskornova type2diabetesatrialfibrillationanddirectoralanticoagulation AT janazolkova type2diabetesatrialfibrillationanddirectoralanticoagulation AT peterkubisz type2diabetesatrialfibrillationanddirectoralanticoagulation AT janstasko type2diabetesatrialfibrillationanddirectoralanticoagulation AT marianmokan type2diabetesatrialfibrillationanddirectoralanticoagulation |